Naturally produced by the soil bacterium Streptomyces avermitili, it is clinically used in the treatment of parasitosis in both humans and animals. This Ivermectin is commercially available as a mixture of 80% 22, 23-dihydroavermectin B1a and 20% 22, 23-dihydroavermectin B1b.
In 2020, Ivermectin indicated that it was a good antiviral agent in the treatment of SARS-CoV-2 and a new mechanism of action has been suggested. Ivermectin would act on importin α/β heterodimer and affect nuclear transport and the translocation of viral proteins.
